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ABSTRACT: There are currently two main techniques allowing the analytical characterization of interchain cysteine-linked 
antibody drug conjugates (ADCs) under non denaturing conditions, namely hydrophobic interaction chromatography 
(HIC) and native mass spectrometry.  HIC is a chromatographic technique allowing the evaluation of drug load profile and 
the calculation of average drug to antibody ratio (DAR). Native mass spectrometry (MS) offers structural insights into mul-
tiple ADC critical quality attributes, thanks to accurate mass measurement. On-line coupling of both techniques can po-
tentially be of great interest, but the presence of large amounts of non-volatile salts in HIC mobile phases make them non 
compatible with MS. Here, we present an innovative multidimensional analytical approach combining comprehensive on-
line two dimensional chromatography that consists of HIC and size exclusion chromatography (SEC) to ion mobility and 
mass spectrometry (IM-MS) for performing analytical characterization of ADCs under non-denaturing conditions. Online 
hyphenation of non-denaturing 2D-chromatography (HICxSEC) to 2D-IM-MS enabled comprehensive and streamlined 
characterization of both native and stressed ADC samples. The proposed 4D methodology could be more generally adapted 
for on-line all-in-one HICxSEC-IMxMS analysis of single protein or protein complexes analysis in non-denaturing condi-
tions. 
INTRODUCTION 
Monoclonal antibodies (mAbs) and their related com-
pounds make up the largest class in human therapeutics to 
treat various diseases. The success of mAbs stems from 
their high specificity and affinity, long circulating half-
lives, ability to induce immune cell effector response, and 
structural versatility.1 However, canonical mAbs often 
show a limited efficacy or face resistance, so several fami-
lies of either armed antibodies (antibody drug conjugates, 
ADCs) or bispecific mAbs (bsAbs) have been developed to 
overcome these limitations. ADCs are tripartite molecules 
consisting of a mAb onto which highly cytotoxic small mol-
ecules are conjugated by cleavable or non-cleavable link-
ers. They show better efficiency than canonical unconju-
gated mAbs, due to the synergic effect of mAb specificity 
for its target and the efficacy of the highly cytotoxic drug.2 
Many of these next generation antibody derivatives, in-
cluding ADCs, have emerged from a better understanding 
of structure–function relationships, which have mainly 
been achieved thanks to state-of-the art mass spectrometry 
(MS) and chromatographic methods. Indeed, ADCs are 
more complex than mAbs, because of the increased inher-
ent micro-variability imparted by the addition of a variable 
number of drug-linkers. Several recent papers have exten-
sively reviewed the advantages, drawbacks and comple-
mentarity of such approaches.3–5 The analytical characteri-
zation of mAb-related compounds usually follows a multi-
level workflow, where biopharmaceuticals are studied at 
the intact protein level (top level), after enzymatic diges-
tion into smaller mAb sub-domains (middle-up level), or 
after proteolytic digestion to generate peptides and glyco-
peptides (bottom-up level).6 Middle- and bottom-up levels 
require preliminary sample treatment that can introduce 
artefact (increased deamidation, oxidation, generation of 
aggregates, etc.). Top level methods performed on intact 
mAbs require less sample handling and are thus of utmost 
interest.7  
The development and optimization of ADCs rely on the 
continuous improvement of  their analytical and bioana-
lytical characterization by assessing several critical quality 
attributes (CQA),8 namely the distribution and position of 
 the cytotoxic drug,9 the amount of naked antibody, the av-
erage drug to antibody (DAR) ratio,10 and the residual 
drug-linker and related product proportions.11 The average 
DAR represents the amount of payloads that can be deliv-
ered to the tumor cell and thus is directly linked to the tox-
icity and the safety of the ADC. The distribution of drug-
loads (i.e. the fraction of antibodies containing zero, one, 
two, three, n drugs) is also an important characteristic, 
since the different isoforms may have different toxicologi-
cal and pharmacological properties.  
As conjugation technologies may result in a highly hetero-
geneous ADC product, with respect to the loading of cyto-
toxic drug species, their position on the mAb and the cleav-
ability of the linker, there is no generic method allowing a 
complete analytical characterization of ADCs. The classical 
denaturing RPLC-MS methods fail for ADC characteriza-
tion, due to the harsh mobile phase conditions employed 
in chromatography (acidic pH, high proportion of organic 
solvent, elevated mobile phase temperature), which dis-
rupt the noncovalent associations between ADC sub-do-
mains.12 The benchmark methods to characterize drug-
load distribution and assess average DAR on ADCs are 
based on chromatography, and particularly hydrophobic 
interaction chromatography (HIC), which separate mAbs 
based on the increased hydrophobicity imparted to the an-
tibody by the increased number of drug conjugates.10,13–16 
However, chromatographic methods that would both sep-
arate individual species and preserve the structure of the 
ADC, like HIC, are not directly amenable to online MS de-
tection.  
Up to now, there are two solutions that were suggested to 
hyphenate HIC with native MS. The first one consists in a 
time consuming off-line coupling performed by peak col-
lection, manual desalting of the fractions and subsequent 
native MS or IM-MS analysis.17 A second alternative ap-
proach was recently proposed and it is based on the online 
combination of HIC and RPLC, using either fully compre-
hensive18 or heart-cutting19 2D-LC strategies. The online 
addition of an RPLC step allows i) the elimination of the 
non-volatile salts contained in the HIC mobile phase and 
ii) the improvement of the resolving power, due to the ad-
ditional chromatographic dimension.20 However, the in-
terchain cysteine-linked ADC samples are denaturated by 
the harsh RPLC conditions,17,21 leading to an indirect and 
more difficult characterization of the complex ADC sam-
ples.   
Because of the need for robust, highly powerful and, if pos-
sible, non-denaturing analytical techniques to answer 
ADCs requirements, we present here a new analytical tech-
nique based on the hyphenation of on-line two-dimen-
sional non-denaturing chromatography involving HIC in 
the first dimension and size exclusion chromatography 
(SEC) in the second one (i.e. HICxSEC), to non-denaturing 
mass spectrometry hyphenated to ion mobility (IM-MS) 
for intact protein therapeutics analysis. As benefits of non-
denaturing MS and its hyphenation to ion mobility (IM-
MS) analysis have already been demonstrated for mAb,22 
ADC,17,23,24 or bsAb17 characterization, we aimed here at a 
direct coupling of this powerful IM-MS strategy with non-
denaturing chromatographic separation by HIC. 
 
EXPERIMENTAL SECTION 
Reagents and materials 
All chemicals were purchased from Sigma-Aldrich : ammo-
nium acetate (A1542), cesium iodide (21004), phosphoric 
acid (345245), 2-propanol (I9516), sodium chloride (S7653), 
sodium phosphate monobasic (S8282), sodium phosphate 
dibasic (S7907). All the aqueous solutions were prepared 
using an ultra-pure water system (Sartorius, Göttingen, 
Germany). Brentuximab vedotin (Adcetris) was from 
Takeda. 
Preparation of thermally stressed ADC solution sam-
ple 
A vial of 50 mg freeze dried brentuximab vedotin was re-
constituted under aseptic conditions with 10 ml water to 
yield a 5 mg/ml solution. Next, 1 ml of the solution was 
transferred in a sterile 1.5 ml tube under a laminar flow 
hood25 and incubated at 40 °C for 4 weeks.  
Instrumentation 
The LCxLC-IMxMS system consists in a combination of H-
Class and I-Class liquid chromatography systems hyphen-
ated to a Synapt G2 HDMS Q-TOF mass spectrometer, 
both from Waters (Manchester, UK). In the first dimen-
sion, the H-Class system includes a high-pressure quater-
nary solvent delivery pump, an autosampler with a flow-
through needle of 15 µL equipped with an extension loop 
of 50 µL. In the second dimension, the I-class system in-
cludes a high-pressure binary solvent delivery pumps, a 
column manager composed of two independent column 
ovens and two 6-port high pressure two-position valves 
acting as interface between the two chromatographic sep-
aration dimensions. A single wavelength UV detector and 
a diode array detector both equipped with 500 nL flow-cell 
were used for the first and second dimension, respectively. 
The dwell volumes were about 425 µL and 300 µL for the 
first and the second dimensions, respectively. It should be 
noted that the dwell volume of the second dimension in-
cludes the volume of sample loops used at the interface 
(i.e. 200 µL). Measured extra-column volumes were 12 µL 
and 17 µL for the first and second dimensions, respectively.  
An external two position switching valve (Vici Valco In-
struments, Houston, USA) was also placed prior to the 
mass spectrometer. Non-denaturing MS and ion mobility 
experiments were performed on a TWIMS-MS Synapt G2 
HDMS instrument (Waters, Manchester, UK). Data acqui-
sition and instrument control were performed with Mass-
Lynx V4.1 software (Waters). 2D-data (UV and TIC) were 
exported to Matlab V7.12.0635 to construct 2D-contour 
plots via house-made calculation routines. MS-Data were 
processed with Masslynx 4.1. 
Chromatographic conditions 
The HIC column was a MabPac HIC-10 (100 mm x 4.6 mm, 
5 µm, 1000 Å) from Thermo Scientific, Cheshire, UK. The 
 SEC column employed in the second dimension was an Ad-
vanceBio SEC (50 mm x 4.6 mm, 2.7 µm, 300 Å) from Ag-
ilent Technologies, Wilmington, DE, USA.  
For the HIC first dimension, the mobile phase A was com-
posed of 2.5 M of ammonium acetate and 0.1 M phosphate 
buffer (Na2HPO4), pH 7.0 (adjusted with phosphoric acid), 
while the mobile phase B was composed of 0.1 M phosphate 
buffer (Na2HPO4 and NaH2PO4) with pH 7.0 (adjusted with 
sodium hydroxide solution). The following gradient was 
employed in HIC: 0 to 90% B in 36 min, 90 to 100% B in 21 
min, followed by an isocratic step at 100% B for 8 min be-
fore re-equilibration during 25 minutes, for a total analysis 
time of 90 min. The HIC experiment was conducted at a 
flow-rate of 100 µL/min. Column temperature, wavelength 
and data acquisition rate were set at 30°C, 280 nm and 10 
Hz respectively. The injection volume was 40 µL.  
For the second chromatographic dimension in SEC, the 
separation was carried out in isocratic mode with an aque-
ous mobile phase composed of 100 mM ammonium acetate 
at a flow-rate of 700 µL/min. Column temperature, wave-
length and data acquisition rate were set at 25 °C, 210 / 280 
nm and 40 Hz respectively. The analysis time of the second 
dimension run corresponds to the sampling time of the 
first dimension separation, namely 1.5 min. A fraction of 
0.45 min (from 0.42 to 0.87 min) was sent to MS thanks to 
a switching valve, to limit salt contamination of the ESI 
source. A flow splitter divided the flow-rate by a factor 7 
prior to entering MS (i.e. inlet flow of 100 µL/min).  
Non-denaturing mass spectrometry conditions 
The Synapt G2 HDMS was operated in sensitive mode and 
positive polarity with a capillary voltage of 3.0 kV. To avoid 
disruption of weak non-covalent interactions, the sample 
cone and pressure in the interface region were set to 160 V 
and 6 mbar, respectively. Source and desolvation tempera-
ture were set to 100 and 450°C, respectively. Desolvation 
and cone gas flows were set at 750 and 60 L/Hr, respec-
tively. Acquisitions were performed in the m/z range of 
1000-10000 with a 1.5 s scan time. External calibration was 
performed using singly charged ions produced by a 2 g/L 
solution of cesium iodide in 2-propanol/water (50/50 v/v). 
Ion mobility mass spectrometry conditions 
For IM-MS measurements, the sample cone voltage was set 
to 100 V and the backing pressure of the source was 6 mbar. 
The Ar flow rate was 5 mL/min and the trap collision en-
ergy was set at 4 V in the traveling-wave-based ion trap. 
Ions were thermalized with a constant He flow rate of 130 
mL/min before IM separation. The height and the velocity 
of the periodic waveform in the pressurized ion mobility 
cell were 40 V and 923 m/s, respectively. N2 was used as 
drift gas (45 mL/min) providing a constant pressure of 2.75 
mbar. Transfer collision energy was fixed to 2 V to extract 
the ions from the IM cell to the TOF analyzer. A calibration 
based on three different proteins (concanavaline A, py-
ruvate kinase and alcohol dehydrogenase) in non-denatur-
ing conditions was used to perform collision cross section 
(CCS) calculation as previously described.26,27  
Average DAR calculation 
The average DAR value represents the sum of relative peak 
area for each DAR multiplied by its corresponding number 
of drugs. It was calculated from HIC chromatogram, by us-
ing Equation 1. 
𝐷𝐴𝑅𝑎𝑣 =  
∑ 𝑘 ∙  𝐴𝑘
8
0
∑ 𝐴𝑘
8
0
 
Where k is the number of drugs and 𝐴𝑘 the HIC peak area 
of DARk.  
 
RESULTS AND DISCUSSION 
Rationale for the 2D-LC-IM-MS design and optimiza-
tion of HICxSEC conditions 
HIC is nowadays considered as the reference technique for 
the analytical characterization of cysteine linked ADC in 
quality control laboratories. In theory, it allows the separa-
tion of the individual DARs on the basis of the number of 
attached drugs and their hydrophobicity. However, in 
many cases, the HIC profile is more complex than expected 
and it becomes difficult to interpret all the potential addi-
tional peaks, which could correspond either to positional 
isomers of DAR species,10 DAR species with an odd number 
of cytotoxic drugs,18 or other type of variants and degrada-
tion products. 
Due to the high amount of non-volatile salts generally em-
ployed in HIC, it is not possible to directly combine this 
chromatographic method with MS detection to identify 
the peaks observed on the HIC profile. For this reason, 
there is a need for eliminating the salts employed in HIC, 
while keeping the non-denaturing advantages offered by 
this chromatographic approach. First, rather than employ-
ing ammonium sulfate as the major component of the mo-
bile phase, ammonium acetate was selected in this study, 
as it is volatile and MS compatible in routine analysis. In 
addition, it was recently demonstrated that a highly similar 
HIC separation of commercial ADC can be obtained with 
both ammonium sulfate and ammonium acetate, assuming 
that the amount of salt was adjusted.14     
Beyond HIC mobile phase modification, which remains in-
sufficient for a straight hyphenation to MS, an additional 
chromatographic dimension (SEC) was added as on-line 
desalting step before the MS inlet (Figure 1). SEC was se-
lected in this setup because it allows a size-based separa-
tion of the species,14 that would allow differentiation of the 
HIC salts (low molecular weights species of < 100 Da) and 
the different isoforms of the ADC (very high molecular 
weight species of > 150,000 Da).  
In order to achieve HICxSEC hyphenation, it was necessary 
to optimize 2D-conditions, starting with the same HIC sep-
aration as the one recently optimized in 18. To achieve a 
very fast SEC separation, which is a prerequisite for on-line 
comprehensive 2D-separation, a short 50 mm SEC column 
was employed at a flow rate corresponding to the maxi-
mum recommended inlet pressure (0.7 mL/min). The use 
of an efficient stationary phase that minimizes non-specific 
interactions with the hydrophobic ADC species28 provided 
sufficient resolving power to discriminate HIC salts and 
ADC samples in the case of low injection volumes. With 1 
 µL injected and a flow-rate of 700 µL/min, ADC species 
(BV) and salts were indeed well separated, leading to sym-
metrical peaks and retention times  of 0.59 min and 0.95 
min respectively (Figure 2a).  
Figure 1. Schematic representation of HICxSEC-IM-MS set-
up. Abbreviations defined as UV: UV detector; DAD: diode ar-
ray detector; SV: switching valve; IM-MS: ion mobility mass 
spectrometer 
However, Figure 2a also shows strong peak distortion 
(broadening and tailing) for both species with 10 and 50 µL 
injected, resulting in resolution decrease and separation 
time increase. In on-line 2D-LC, much larger injection vol-
umes are required since the two separations are linked by 
the sampling time. As a result, the sampling time has to be 
long enough to achieve the separation in the second di-
mension (2D) and short enough to send a sufficient num-
ber of fractions in 2D while keeping the separation in the 
first dimension (1D). The effective resolution in 1D can be 
strongly affected by under-sampling resulting from the ne-
cessity to send large fractions in the second dimension. In 
the meantime, as shown in Figure 2b, large injection vol-
umes affect the peak shapes in the second dimension and 
hence the effective resolution. In our HIC conditions, the 
obtained minimum resolution was 1.5. The loss in resolu-
tion should therefore not exceed 30% (i.e. Rs>1) to main-
tain a sufficient separation between all pairs of peaks. Ac-
cording to the relationship established by Davis et al. to 
correct the resolution from under-sampling,29 a loss of 30% 
corresponds to a sampling rate of 2.7. Considering the 1D 
peak widths (i.e. about 400 µl) obtained with the optimized 
HIC gradient, fractions of 150 µL or less have to be sent in 
the second dimension. In case of 150 µL, a 2D analysis time 
of 1.5 min was required to achieve the complete elution of 
the salts, leading to a 1D flow-rate of 100 µL/min (i.e. 
150/1.5). Reducing the injection volume and hence the sep-
aration time in 2D could be a good option to increase the 
resolution in the second dimension. However, as can be 
shown in Figure 2a, the separation time is still 1.3 min with 
only 50 µL injected, thereby leading to a lower 1D-flow-rate 
(i.e. 40 µL/min) and hence to a longer 1D-analysis time. 
Furthermore, reducing the injection volume in 2D would 
also lead to increase sample dilution. In light of the above 
considerations, a sampling time of 1.5 min and a 1D-flow-
rate of 100 µL/min were selected (150 µL injected in the sec-
ond dimension). The resulting separation of a HIC fraction 
of BV on the SEC column is shown in Figure 2b. As shown, 
the baseline resolution between the two peaks was not ob-
tained in these conditions, due to strong injection effects. 
The two vertical lines in Figure 2b delimit a fraction with 
no salts, which could be sent to MS thanks to a two-posi-
tion switching valve located between the SEC column out-
let and the MS inlet. The rest of the SEC separation was 
sent to the waste (Figure 1). It is important to mention that, 
rather than a multiple heart-cutting methodology, a fully 
comprehensive on-line HICxSEC approach was considered 
in this study. The optimized 2D-HICxSEC method was next 
hyphenated with high resolution native MS (3 dimensional 
approach), to achieve the identification of all the peaks ob-
served in HIC for a cysteine linked ADC sample, without 
any denaturation. Finally, ion mobility (IM) was activated 
simultaneously to MS to have a conformational character-
ization of each HIC peak (4 dimensional approach). An 
overall schematic workflow of the fully comprehensive on-
line HICxSEC-IMxMS strategy is provided in Figure 3. This 
HICxSEC-IMxMS configuration allowed maintaining the 
integrity of HIC 1D-separation, while providing a global MS 
picture of the ADC sample under non-denaturing condi-
tions within a single run, by disclosing the most exhaustive 
information.  
Figure 2. Effect of injection volume on the SEC separation of 
brentuximab vedotin and ammonium acetate: (a) 1µL,  10µL 
and 50µL of a sample containing 2.5M ammonium acetate and 
brentuximab vedotin 0.4mg/mL, injected in 1D-SEC; (b) HIC-
fraction of 150 µL of brentuximab vedotin injected in 2D-SEC. 
Vertical lines delimit the SEC-fraction sent to MS. Other con-
ditions given in the experimental section. 
 
HICxSEC-IMxMS analysis the reference cysteine-
linked ADC, brentuximab vedotin (BV, Adcetris). 
As a proof-of-concept, we first analyzed BV, the reference 
cysteine linked ADC, on the previously described 4D HICx-
SEC-IMxMS system (Figure 3). Optimized HIC chromato-
gram was obtained in a first dimension for BV using am-
monium acetate as mobile phase without any sample prep-
aration (no deglycosylation, no buffer exchange, Figure 
4a). Each 1.5 min long HIC segment was continuously sent 
 onto the second dimension SEC column, enabling on-line, 
continuous fast buffer exchange of each individual high-
salt containing HIC segment. All the SEC fractions were 
then continuously infused into a MS equipped with an IM 
separator via an electrospray ionization (ESI) source oper-
ating under non-denaturing conditions. IM conforma-
tional characterization and native MS provide the third 
and fourth dimensions of our approach, respectively. 
As expected, five main peaks were detected after the 1D-
HIC separation of BV (Figure 4a), which were all unambig-
uously identified by non-denaturing MS intact mass meas-
urement (Figure 4b right panel and Table 1). All detected 
species could be identified as drug load species (D0 to D8) 
with a mass accuracy between 100-160 ppm, which is clas-
sical for intact ADC analysis in non-denaturing conditions 
on Q-TOF instruments17,23 and very good, considering the 
short acquisition time of only 0.45 min. Of note, even mi-
nor HIC species like D0 or D8 were clearly identified by 
non-denaturing MS. Therefore, average DAR determina-
tion is not anymore performed on the basis of species iden-
tification from HIC retention times, but on more accurate 
MS identification. For BV, an average DAR of 4.0 was un-
ambiguously determined (Table 1), which is in agreement 
with expected values.17,30 To add an on-line additional di-
mension for conformational characterization, we next 
turned on the ion mobility of our MS, resulting in compre-
hensive 2D-IM-MS analysis of BV in non-denaturing con-
ditions (Figure 4b, left panel). Arrival time distributions 
(ATDs) of each individual species could be isolated in the 
IM cell, allowing conformational characterization through 
TWCCSN2 calculations of each HICxSEC separated drug load 
species (Figure 4b, middle panel). IM analyses led to the 
determination of the conformational homogeneity of each 
individual HIC fraction, as already reported for off-line 
HIC-IMxMS analysis in non-denaturing conditions.17 Fig-
ure 4b (left panel) presents the IMxMS contour plots of 
each individual HIC-detected species. A good agreement 
was obtained between TWCCSN2 values obtained by HICx-
SEC-IMxMS and those obtained by off-line injection of 
manually desalted BV (Table 1), demonstrating that the 
2D-HICxSEC configuration does not affect BV global con-
formation. Altogether, our results demonstrate for the first 
time the ability to have a comprehensive analytical charac-
terization of a cysteine-linked ADC within a single run, af-
fording i) simultaneous drug load profile and quantitative 
average DAR assessment (HIC), ii) the unambiguous iden-
tification of the number of drug conjugations through ac-
curate intact mass measurement in non-denaturing condi-
tions (native MS), along with iii) conformational homoge-
neity assessment of each drug load species (native IM).
 
 
Figure 3. Flowchart of the analysis for brentuximab vedotin.
 Figure 4. Online HICxSEC-IMxMS of brentuximab vedotin. HIC profile (a) and IM-MS characterization (b). For each indi-
vidual DAR, zoom of the 13−18 ms td region of the driftscope plots (b, left panel), individual ATDs corresponding to the 27+ 
charge state (b, central panel), and deconvoluted native mass spectra (b, right panel) were represented. 
 
Application of HICxSEC-IMxMS in non-denaturing 
conditions for thermally stressed samples 
To highlight the possibilities and relevance of this new 4D 
approach involving chromatographic and mass spectro-
metric methods, we next compared intact BV and temper-
ature stressed BV samples (see material and methods). A 
comparison of the HICxSEC 2D-contour plots of stressed 
and non-stressed BV is shown in Figures 5a and 5b, respec-
tively. As reported in one of our previous study in 
HICxRPLC-MS,18 the 2D-HICxSEC contour plots of 
stressed BV clearly highlight increase in intensities of 
DAR0 species along with species eluted at retention times 
which are intermediate between DAR0 and DAR2, and be-
tween DAR2 and DAR4, respectively. In addition, the in-
tensities of the DAR6 and DAR8 peaks significantly de-
crease, while the DAR0 peak increases (Table 1 and com-
parison of Figures 5a and 5b). The direct on-line coupling 
of non-denaturing MS to HICxSEC separation allowed first 
to accurately measure the molecular weights of all the 
compounds and to unambiguous identify DAR1 and DAR3 
odd DARs as species formed upon thermal stress (Figures 
5c and 5d). Of note, only an averaged mass of all the glyco-
form could be measured for DAR1 and DAR3 species in un-
stressed BV sample due to very low intensity MS signals 
hampering accurate mass measurements. Conversely, as 
DAR1 and DAR3 species because more abundant in 
stressed BV sample, accurate mass measurement of the 
most intense glycoform could be performed (Table 1). 
Thanks to MS identification of all the detected species, the 
average DAR calculated from the HIC chromatogram was 
reduced down to 2.8 in stressed conditions compared to 
4.0 (Table 1), which is in agreement with previously pub-
lished data.18 Simultaneously, on-line non-denaturing IM 
analysis allowed direct and unambiguous conformational 
characterization of odd DARs species (DAR1 and DAR3) 
through their TWCCSN2 calculations (Table 1).  
  
Table 1. Summary of experimental values for the different DARs of non-stressed and stressed ADC: molecular weights 
obtained from mass spectra, experimental collision cross section (TWCCSHe), HIC peak area and average DAR calculation. 
Abbreviations are defined as ND for not detected. Experimental masses of DARs were compared to the theoretical ones. 
Experimental collision cross sections obtained from centroid IM drift times were compared with predicted CCSHe calculated 
through the equation CCS=2.435*M2/3 for spherical proteins.27  
 
 
DAR 
(G1F/G0F) 
D0 D1 D2 D3 D4 D5 D6 D7 D8 
 
Theoretical 
mass (Da) 
148242 149559 150877 152195 153512 154830         156148 157465 158783 
N
o
n
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e
ss
ed
 
Experimental 
mass (Da) 
148259 
± 6 
149756 * Av-
erage mass 
150901 
± 3 
152479 * Av-
erage mass  
153538 ± 
7 
ND 
156169 ± 
8 
ND 
158800 ± 
6 
 
Mass accuracy 
(ppm) 
116 - 157 - 166 - 137 - 106 
TWCCSHe (nm2) 70.9 - 71.4 - 71.8 - 72.1 - 72.5 
 Pred CCSHe 
(nm2) 
68.2 - 69.0 - 69.8 - 70.6 - 71.4 
HIC peak area 
(%) 
5.8 1.8 24.1 4.3 32.8 - 21.5 - 9.7 
Average 
DAR 4.0 
St
re
ss
ed
 
Experimental 
mass (Da) 
148257 
± 7  
149588  
± 5 
150900 
± 5 
152221  
± 25 
153535 ± 
40 
ND 
156167 ± 
21 
ND 
158818 ± 
17 
 
Mass accuracy 
(ppm) 
105 193 151 171 150 - 124 - 222 
TWCCSHe (nm2) 70.8 70.8 71.5 71.7 71.9 - 72.3 - 72.6 
 Pred CCSHe 
(nm2) 
68.2 68.6 69.0 69.4 69.8 - 70.6 - 71.4 
HIC peak area 
(%) 
13.5 10.6 25.9 7.3 33.4 - 8.2 - 1.1 
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Figure 5. 2D-HICxSEC contour plots of brentuximab Vedotin (a) and stressed brentuximab vedotin (b). IM-MS structural 
characterization of odd DAR species (c-d) of stressed (black lines) and not stressed (grey lines) brentuximab vedotin. Indi-
vidual ATDs corresponding to the 27+ charge state (c-d, left panels), and native mass spectra (c-d, right panels) of DAR1 (c) 
and DAR3 (d) were represented. 
 In addition, comparison of normalized extracted ATDs of 
unstressed versus stressed BV clearly highlights the inten-
sity increase of odd DAR species in forced degradation con-
ditions (Figures 5c and 5d). Altogether, these results pro-
vide a first proof-of-concept for using a comprehensive 4D 
HICxSEC-IMxMS methodology to assess the structure of 
hinge cysteine ADCs. 
 
CONCLUSIONS 
We have presented here an innovative multidimensional 
analytical approach combining comprehensive on-line two 
dimensional chromatography (HICxSEC) to ion mobility 
and mass spectrometry (IM-MS) for performing analytical 
characterization of ADCs under non-denaturing condi-
tions. On-line hyphenation of non-denaturing comprehen-
sive 2D-chromatography to 2D-IMxMS enabled compre-
hensive and streamlined characterization of both native 
and stressed cysteine ADC samples. The combination of 
HIC and IMxMS using a 2D-setup through a SEC desalting 
step allows obtaining in-depth and detailed information on 
ADC samples that cannot be reached from HIC-UV or non-
denaturing mass spectrometry alone. The all-in-one ana-
lytical strategy described here permits a deep, straightfor-
ward and rapid characterization of complex ADC samples. 
In comparison to heart-cutting (or multiple heart-cutting) 
procedure, the most exhaustive information can be 
reached from the investigated sample using the compre-
hensive 2D-strategy. As example, DAR1 and DAR3 species 
were observed with the comprehensive 2D-approach, 
while this will probably not be the case with a heart-cutting 
approach. Such approach would be of great interest for ex-
ample to assess the structure of ADCs derived from re-
duced interchain Cysteine and chemically crosslinked 
("rebridged”).31–33  
The ability to have an on-line direct coupling of HIC to 
non-denaturing MS using 4D HICxSEC-IMxMS technique 
will have a strong impact on the analytical characterization 
of ADCs and next generation empowered ADC formats like 
bispecific ADCs or dual ADCs as well as more generally for 
proteins.34 Several ADC quality attributes required for pro-
cess and formulation development, routine lot-release, and 
stability testing can be monitored within one unique run 
using our 4D HICxSEC-IMxMS methodology. First, the 
gold standard HIC profile allows unambiguous drug load 
profile assessment. Its on-line hyphenation to non-dena-
turing MS (through on-line fast SEC desalting) brings the 
unique advantage of a clear and unambiguous identifica-
tion of each chromatographic peak, through an accurate 
high resolution mass measurement along with conforma-
tional IM-MS characterization. As a result, the identifica-
tion of each DAR species is straightforward and subse-
quent average DAR assessment more accurate. In addition, 
drug load profiles are obtained without any extensive sam-
ple preparation from the HIC chromatogram. Finally, the 
conformational IM separation allows global conforma-
tional homogeneity assessment of each peak. Altogether, 
the described 4D HICxSEC-IMxMS approach could be pro-
posed as the first multi-attribute method35 in non-denatur-
ing conditions for intact cysteine-linked ADC characteri-
zation that combines the power of chromatographic sepa-
ration to the specificity of mass spectrometric identifica-
tion. 
Our innovative 4D HICxSEC-IMxMS can potentially be ex-
tended to the analysis of several other protein families, as 
HIC is a robust standard analytical method for protein 
analysis  which preserves their biological activity.34 For in-
stance, HIC is widely used to study post-translational mod-
ifications of proteins and drug-protein interactions. Re-
cently, HIC has also been off-line combined to bottom up 
RPLC-MS/MS proteomics for single proteins or protein 
complexes analysis.36–38 In this context, our on-line 4D 
methodology could be envisioned for the on-line bottom 
up LC-MS/MS analysis of protein complexes in non-dena-
turing conditions. In addition, the first HIC dimension 
could be replaced by any other non-denaturing chromato-
graphic methods like ion exchange (IEX) or size exclusion 
chromatography (SEC), enlarging the possibilities offered 
by our approach. More generally, the developed 4D HICx-
SEC-IMxMS methods will open new ways for single pro-
teins or protein complexes analysis in non-denaturing con-
ditions. 
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